Skip to main content
SpringerLink
Log in

Alternative Therapies for Cytokine Storm Syndromes

  • Chapter
  • First Online:
Cytokine Storm Syndrome

  • 1457 Accesses

Abstract

Cytokine storm syndromes (CSS) are a challenge for physicians, both due to their aggressive nature and the need for tailored treatment for each patient. While hematopoietic stem cell transplantation (HSCT) has changed the fate of primary hemophagocytic lymphohistiocytosis (HLH), and biologics of macrophage activation syndrome (MAS)/secondary HLH, there is still a need for adjunctive treatment to better manage these patients. The principles of treatment are summarized in Table 1. This chapter discusses the available alternative treatments (biologics discussed in elsewhere). Unfortunately, except for corticosteroids, there is not a lot of solid evidence for the effectiveness of most of these agents. Biologics have become an essential part of the treatment in MAS. However for all these treatment modalities and corticosteroids, there is a lack of controlled studies to guide optimal dosage and duration of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Janka, G. E., & Lehmberg, K. (2013). Hemophagocytic lymphohistiocytosis: Pathogenesis and treatment. Hematology American Society of Hematology Education Program., 2013, 605–611.

    Article  PubMed  Google Scholar 

  2. Tothova, Z., & Berliner, N. (2015). Hemophagocytic syndrome and critical illness: New insights into diagnosis and management. Journal of Intensive Care Medicine., 30(7), 401–412.

    Article  PubMed  Google Scholar 

  3. Schulert, G. S., & Grom, A. A. (2014). Macrophage activation syndrome and cytokine-directed therapies. Best Practice & Research Clinical Rheumatology., 28(2), 277–292.

    Article  Google Scholar 

  4. Mouy, R., Stephan, J. L., Pillet, P., Haddad, E., Hubert, P., & Prieur, A. M. (1996). Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases. The Journal of Pediatrics., 129(5), 750–754.

    Article  CAS  PubMed  Google Scholar 

  5. Ravelli, A., De Benedetti, F., Viola, S., & Martini, A. (1996). Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. The Journal of Pediatrics., 128(2), 275–278.

    Article  CAS  PubMed  Google Scholar 

  6. Trottestam, H., Horne, A., Arico, M., Egeler, R. M., Filipovich, A. H., Gadner, H., et al. (2011). Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood, 118(17), 4577–4584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Henter, J. I., Horne, A., Arico, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., et al. (2007). HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer., 48(2), 124–131.

    Article  Google Scholar 

  8. Ravelli, A., Grom, A. A., Behrens, E. M., & Cron, R. Q. (2012). Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment. Genes and Immunity., 13(4), 289–298.

    Article  CAS  PubMed  Google Scholar 

  9. Coca, A., Bundy, K. W., Marston, B., Huggins, J., & Looney, R. J. (2009). Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin. Clinical Immunology., 132(1), 10–18.

    Article  CAS  PubMed  Google Scholar 

  10. Mahlaoui, N., Ouachee-Chardin, M., de Saint Basile, G., Neven, B., Picard, C., Blanche, S., et al. (2007). Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients. Pediatrics, 120(3), e622–e628.

    Article  PubMed  Google Scholar 

  11. Ouachee-Chardin, M., Elie, C., de Saint Basile, G., Le Deist, F., Mahlaoui, N., Picard, C., et al. (2006). Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: A single-center report of 48 patients. Pediatrics, 117(4), e743–e750.

    Article  PubMed  Google Scholar 

  12. Bennett, T. D., Fluchel, M., Hersh, A. O., Hayward, K. N., Hersh, A. L., Brogan, T. V., et al. (2012). Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis and Rheumatism, 64(12), 4135–4142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sawhney, S., Woo, P., & Murray, K. J. (2001). Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Archives of Disease in Childhood., 85(5), 421–426.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wallace, C. A., & Sherry, D. D. (1997). Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis and Rheumatism, 40(10), 1852–1855.

    Article  CAS  PubMed  Google Scholar 

  15. Chighizola, C. B., Ong, V. H., & Meroni, P. L. (2017). The use of cyclosporine A in rheumatology: A 2016 comprehensive review. Clinical Reviews in Allergy & Immunology., 52(3), 401–423.

    Article  CAS  Google Scholar 

  16. Bergsten, E., Horne, A., Arico, M., Astigarraga, I., Egeler, R. M., Filipovich, A. H., et al. (2017). Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long term results of the cooperative HLH-2004 study. Blood.

    Google Scholar 

  17. Takahashi, H., Tsuboi, H., Kurata, I., Takahashi, H., Inoue, S., Ebe, H., et al. (2015). Predictors of the response to treatment in acute lupus hemophagocytic syndrome. Lupus, 24(7), 659–668.

    Article  CAS  PubMed  Google Scholar 

  18. Parodi, A., Davi, S., Pringe, A. B., Pistorio, A., Ruperto, N., Magni-Manzoni, S., et al. (2009). Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty-eight patients. Arthritis and Rheumatism, 60(11), 3388–3399.

    Article  CAS  PubMed  Google Scholar 

  19. Gokce, M., Bilginer, Y., Besbas, N., Ozaltin, F., Cetin, M., Gumruk, F., et al. (2012). Hematological features of pediatric systemic lupus erythematosus: Suggesting management strategies in children. Lupus, 21(8), 878–884.

    Article  CAS  PubMed  Google Scholar 

  20. Thompson, P. A., Allen, C. E., Horton, T., Jones, J. Y., Vinks, A. A., & McClain, K. L. (2009). Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer., 52(5), 621–625.

    Article  Google Scholar 

  21. Mouthon L, Lacroix-Desmazes S, Pashov A, Kaveri SV, Kazatchkine MD. (1999). [Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases]. La Revue De Medecine Interne. (20 Suppl 4):423s–430s.

    Google Scholar 

  22. Guilpain, P., Chanseaud, Y., Tamby, M. C., Larroche, C., Guillevin, L., Kaveri, S. V., et al. (2004). Immunomodulatory effects of intravenous immunoglobulins. Presse Médicale, 33(17), 1183–1194.

    Article  PubMed  Google Scholar 

  23. Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M., & Cron, R. Q. (2011). Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients. Rheumatology, 50(2), 417–419.

    Article  CAS  PubMed  Google Scholar 

  24. Boom, V., Anton, J., Lahdenne, P., Quartier, P., Ravelli, A., Wulffraat, N. M., et al. (2015). Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatric Rheumatology Online Journal., 13, 55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Alvarez-Cardona, A., Rodriguez-Lozano, A. L., Blancas-Galicia, L., Rivas-Larrauri, F. E., & Yamazaki-Nakashimada, M. A. (2012). Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease. Journal of Clinical Immunology, 32(2), 207–211.

    Article  PubMed  Google Scholar 

  26. Parekh, C., Hofstra, T., Church, J. A., & Coates, T. D. (2011). Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatric Blood & Cancer., 56(3), 460–462.

    Article  Google Scholar 

  27. Martin, A., Marques, L., Soler-Palacin, P., Caragol, I., Hernandez, M., Figueras, C., et al. (2009). Visceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease. The Pediatric Infectious Disease Journal., 28(8), 753–754.

    Article  PubMed  Google Scholar 

  28. Emmenegger, U., Frey, U., Reimers, A., Fux, C., Semela, D., Cottagnoud, P., et al. (2001). Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. American Journal of Hematology., 68(1), 4–10.

    Article  CAS  PubMed  Google Scholar 

  29. Larroche, C., Bruneel, F., Andre, M. H., Bader-Meunier, B., Baruchel, A., Tribout, B., et al. (2000). Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP. Annales De Medecine Interne., 151(7), 533–539.

    CAS  PubMed  Google Scholar 

  30. Rajajee, S., Ashok, I., Manwani, N., Rajkumar, J., Gowrishankar, K., & Subbiah, E. (2014). Profile of hemophagocytic lymphohistiocytosis; efficacy of intravenous immunoglobulin therapy. Indian Journal of Pediatrics., 81(12), 1337–1341.

    Article  PubMed  Google Scholar 

  31. Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly-Smith, L., Delaney, M., et al. (2016). Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The seventh special issue. Journal of Clinical Apheresis., 31(3), 149–162.

    PubMed  Google Scholar 

  32. Matsumoto, Y., Naniwa, D., Banno, S., & Sugiura, Y. (1998). The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: Two case reports. Therapeutic Apheresis, 2(4), 300–304.

    Article  CAS  PubMed  Google Scholar 

  33. Satomi, A., Nagai, S., Nagai, T., Niikura, K., Ideura, T., Ogata, H., et al. (1999). Effect of plasma exchange on refractory hemophagocytic syndrome complicated with myelodysplastic syndrome. Therapeutic Apheresis, 3(4), 317–319.

    Article  CAS  PubMed  Google Scholar 

  34. Song, K. S., & Sung, H. J. (2006). Effect of plasma exchange on the circulating IL-6 levels in a patient with fatal hemophagocytic syndrome associated with bile ductopenia. Therapeutic Apheresis and Dialysis, 10(1), 87–89.

    Article  PubMed  Google Scholar 

  35. Nakakura, H., Ashida, A., Matsumura, H., Murata, T., Nagatoya, K., Shibahara, N., et al. (2009). A case report of successful treatment with plasma exchange for hemophagocytic syndrome associated with severe systemic juvenile idiopathic arthritis in an infant girl. Therapeutic Apheresis and Dialysis, 13(1), 71–76.

    Article  CAS  PubMed  Google Scholar 

  36. Demirkol, D., Yildizdas, D., Bayrakci, B., Karapinar, B., Kendirli, T., Koroglu, T. F., et al. (2012). Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: What is the treatment? Critical Care., 16(2), R52.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kaieda, S., Yoshida, N., Yamashita, F., Okamoto, M., Ida, H., Hoshino, T., et al. (2015). Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Modern Rheumatology., 25(6), 962–966.

    Article  CAS  PubMed  Google Scholar 

  38. Mokrzycki, M. H., & Kaplan, A. A. (1994). Therapeutic plasma exchange: Complications and management. American Journal of Kidney Diseases, 23(6), 817–827.

    Article  CAS  PubMed  Google Scholar 

  39. Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2005). The biology of CD20 and its potential as a target for mAb therapy. Current Directions in Autoimmunity., 8, 140–174.

    Article  CAS  PubMed  Google Scholar 

  40. Chellapandian, D., Das, R., Zelley, K., Wiener, S. J., Zhao, H., Teachey, D. T., et al. (2013). Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. British Journal of Haematology., 162(3), 376–382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Park, H. S., Kim, D. Y., Lee, J. H., Lee, J. H., Kim, S. D., Park, Y. H., et al. (2012). Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: An analysis of treatment outcome and prognostic factors. Annals of Hematology., 91(6), 897–904.

    Article  CAS  PubMed  Google Scholar 

  42. Jordan, M. B., Allen, C. E., Weitzman, S., Filipovich, A. H., & McClain, K. L. (2011). How I treat hemophagocytic lymphohistiocytosis. Blood, 118(15), 4041–4052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Behrens, E. M., & Koretzky, G. A. (2017). Review: Cytokine storm syndrome: looking toward the precision medicine era. Arthritis & Rheumatology., 69(6), 1135–1143.

    Article  Google Scholar 

  44. Kimby, E. (2005). Tolerability and safety of rituximab (MabThera). Cancer Treatment Reviews., 31(6), 456–473.

    Article  CAS  PubMed  Google Scholar 

  45. Tesfa, D., & Palmblad, J. (2011). Late-onset neutropenia following rituximab therapy: Incidence, clinical features and possible mechanisms. Expert Review of Hematology., 4(6), 619–625.

    Article  CAS  PubMed  Google Scholar 

  46. Hernandez-Campo, P. M., Almeida, J., Sanchez, M. L., Malvezzi, M., & Orfao, A. (2006). Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: A frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry Part B, Clinical Cytometry., 70(2), 71–81.

    Article  PubMed  CAS  Google Scholar 

  47. Xia, M. Q., Tone, M., Packman, L., Hale, G., & Waldmann, H. (1991). Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. European Journal of Immunology, 21(7), 1677–1684.

    Article  CAS  PubMed  Google Scholar 

  48. Strout, M. P., Seropian, S., & Berliner, N. (2010). Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nature Reviews Clinical Oncology., 7(7), 415–420.

    Article  PubMed  Google Scholar 

  49. Gerard, L. M., Xing, K., Sherifi, I., Granton, J., Barth, D., Abdelhaleem, M., et al. (2012). Adult hemophagocytic lymphohistiocytosis with severe pulmonary hypertension and a novel perforin gene mutation. International Journal of Hematology., 95(4), 445–450.

    Article  PubMed  Google Scholar 

  50. Marsh, R. A., Allen, C. E., McClain, K. L., Weinstein, J. L., Kanter, J., Skiles, J., et al. (2013). Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatric Blood & Cancer., 60(1), 101–109.

    Article  CAS  Google Scholar 

  51. Marsh, R. A., Jordan, M. B., Talano, J. A., Nichols, K. E., Kumar, A., Naqvi, A., et al. (2017). Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience. Pediatric Blood & Cancer. 64(4).

    Google Scholar 

  52. Cooper, N., Rao, K., Gilmour, K., Hadad, L., Adams, S., Cale, C., et al. (2006). Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood, 107(3), 1233–1236.

    Article  CAS  PubMed  Google Scholar 

  53. Marsh, R. A., Vaughn, G., Kim, M. O., Li, D., Jodele, S., Joshi, S., et al. (2010). Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood, 116(26), 5824–5831.

    Article  CAS  PubMed  Google Scholar 

  54. Cooper, N., Rao, K., Goulden, N., Webb, D., Amrolia, P., & Veys, P. (2008). The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplantation., 42(Suppl 2), S47–S50.

    Article  PubMed  Google Scholar 

  55. Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., et al. (2016). Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 127(13), 1666–1675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Maschalidi, S., Sepulveda, F. E., Garrigue, A., Fischer, A., & de Saint Basile, G. (2016). Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood, 128(1), 60–71.

    Article  CAS  PubMed  Google Scholar 

  57. Sin, J. H., & Zangardi, M. L. (2017). Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. Hematology/Oncology and Stem Cell Therapy.

    Google Scholar 

  58. Slostad, J., Hoversten, P., Haddox, C. L., Cisak, K., Paludo, J., & Tefferi, A. (2018). Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. American Journal of Hematology., 93(2), E47–E49.

    Article  PubMed  Google Scholar 

  59. Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., et al. (2012). Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. The New England Journal of Medicine, 367(6), 495–507.

    Article  CAS  PubMed  Google Scholar 

  60. Naithani, R., Asim, M., Naqvi, A., Weitzman, S., Gassas, A., Doyle, J., et al. (2013). Increased complications and morbidity in children with hemophagocytic lymphohistiocytosis undergoing hematopoietic stem cell transplantation. Clinical Transplantation, 27(2), 248–254.

    Article  PubMed  Google Scholar 

  61. Ohga, S., Kudo, K., Ishii, E., Honjo, S., Morimoto, A., Osugi, Y., et al. (2010). Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatric Blood & Cancer, 54(2), 299–306.

    Google Scholar 

  62. Janka, G. E. (1983). Familial hemophagocytic lymphohistiocytosis. European Journal of Pediatrics., 140(3), 221–230.

    Article  CAS  PubMed  Google Scholar 

  63. Fischer, A., Cerf-Bensussan, N., Blanche, S., Le Deist, F., Bremard-Oury, C., Leverger, G., et al. (1986). Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. The Journal of Pediatrics., 108(2), 267–270.

    Article  CAS  PubMed  Google Scholar 

  64. Horne, A., Janka, G., Maarten Egeler, R., Gadner, H., Imashuku, S., Ladisch, S., et al. (2005). Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. British Journal of Haematology., 129(5), 622–630.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Hacettepe University, Ankara, Turkey

    Seza Ozen & Saliha Esenboga

Authors
  1. Seza Ozen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saliha Esenboga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. UAB School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

    Randy Q. Cron

  2. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Edward M. Behrens

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ozen, S., Esenboga, S. (2019). Alternative Therapies for Cytokine Storm Syndromes. In: Cron, R., Behrens, E. (eds) Cytokine Storm Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-030-22094-5_34

Download citation

Publish with us

Policies and ethics

Search

Navigation